DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquı́n Mateo, Johann S. de Bono, Emma Hall et al.|New England Journal of Medicine|2015Cited by 2.2k
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Johann S. de Bono, Joaquı́n Mateo et al.|Cancer Discovery|2017Cited by 422
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Johann S. de Bono, Núria Porta et al.|Cancer Discovery|2021Cited by 161
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone SensitivityGunther Boysen, Johann S. de Bono, Daniel Nava Rodrigues et al.|Clinical Cancer Research|2018Cited by 140
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Johann S. de Bono, Adam Sharp et al.|Nature|2023Cited by 119